NASDAQ · Medical - Pharmaceuticals

Azora Therapeutics, Inc. (AZR) Stock Price & Fundamentals

$3.81 -6.85% NASDAQ: AZR Healthcare

Data as of Nov 16, 2026 (intraday, delayed) · Statements through the quarter ended Sep 2026 · Source: Financial Modeling Prep (methodology)

Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.

Valuation

MetricValue
Price$3.81
Market Cap$10.00M
P/E Ratio-0.20
P/B Ratio3117.50
P/S Ratio0.00
EPS (TTM)−$11.93
52-Week High$8.25
52-Week Low$1.31
Dividend Yield0.00%

Financials & Margins

MetricValue
ROE-160.00%
ROA-114.29%
ROCE-264.70%
Gross Margin0.00%
Operating Margin0.00%
Net Margin0.00%
Debt/Equity0.00
Current Ratio4.43

Azora Therapeutics, Inc. key facts

Strengths in the numbers

  • Debt/equity 0.00, below the 0.59 median across 6 Medical - Pharmaceuticals peers (largest by market cap).

Points to check

  • Cash from operations was negative in each of the last 5 fiscal years.
  • Free cash flow was negative in each of the last 5 fiscal years.

Computed by rule from the reported figures on this page. A description of the numbers, not advice.

Peer Comparison

TickerPriceChangeP/EMarket CapDiv Yield
RPRXRoyalty Pharma plc $68.54 -1.12% 41.25 $30.52B 1.35%
CORTCorcept Therapeutics Incorporated $69.46 -4.77% 49.69 $7.60B 0.00%
LQDALiquidia Corporation $56.37 -1.81% — $5.08B 0.00%
PBHPrestige Consumer Healthcare Inc. $48.05 +4.03% 13.90 $2.28B 0.00%
QUITAchieve Life Sciences, Inc. $6.11 -3.32% — $628.73M 0.00%
HITIHigh Tide Inc. $2.38 -3.85% — $211.71M 0.00%
TRXBTRex Bio Inc. $11.83 -13.46% — $98.54M 0.00%
LLYEli Lilly and Company $1434.26 -0.64% 42.60 $1.35T 0.54%

Quarterly Results — Last 4 Quarters (USD millions)

MetricDec '25Mar '26Jun '26Sep '26
Sales$0$0$0$0
Operating Profit−$2.0M−$2.0M−$52.0M−$8.0M
Net Profit−$2.0M−$2.0M−$52.0M−$65.0M
EPS−$1.80−$1.48−$11.25−$4.52

Annual Financials (USD)

Metric2025
Revenue$0
Operating Profit−$8.0M
Net Profit−$8.0M
EPS−$11.93
Op Margin—

AZR fundamentals by fiscal year

AZR has only 1 fiscal year on file — at least 3 are needed to draw a trend. The annual table above shows what is available.

Balance Sheet (USD)

Metric2025
Total Assets$7.0M
Total Liabilities$2.0M
Cash$6.0M
Borrowings$0

Cash Flow (USD)

Metric20212022202320242025
Operating Cash Flow−$12.0M−$11.0M−$7.0M−$7.0M−$6.0M
Investing Cash Flow$0—$2.0M—$0
Financing Cash Flow$14.0M$9.0M$4.0M$8.0M$8.0M
Net Cash Flow$2.0M−$2.0M−$1.0M$1.0M$2.0M
Free Cash Flow−$12.0M−$11.0M−$7.0M−$7.0M−$6.0M

Efficiency Ratios (fiscal years)

ROCE is profit before interest and tax divided by total assets less current liabilities. Payable days and the cash conversion cycle need a trade-payables line, which these statements do not carry.

Metric2025
ROCE %-133.3%
ROE %-160.0%

Valuation & Return Ratios

MetricValue
PEG Ratio0.00
EV / EBITDA-0.16
FCF Yield-92.95%
Quick Ratio4.43
Interest Coverage—
Return 1Y-53.82%
Return 3Y-92.74%
Return 5Y-99.82%

Filings & documents

Azora Therapeutics, Inc. (AZR) reports filed with the US Securities and Exchange Commission, newest first. SEC CIK 0001513525. Links open sec.gov.

Annual reports (10-K)

Latest: 10-K for fiscal 2025 (period ended 31 Dec 2025), filed 5 Mar 2026. Document · Filing index

Quarterly reports (10-Q)

Labelled by the quarter's period end.

Recent events (8-K)

  • Results of operations8-KPress release (EX-99.1)
  • Director/officer change; Other events8-K
  • Director/officer change; Charter or bylaw amendment; Shareholder vote results; Regulation FD disclosure8-K
  • Other events8-K
  • Other events8-K

Proxy statements (DEF 14A)

Source: SEC EDGAR, checked 16 Nov 2026. All filings on SEC EDGAR

Latest News

Azora Therapeutics Appoints Board of Directors with Extensive Drug Development and Inflammatory Bowel Disease Expertise GlobeNewswire · Nov 5, 2026

About Azora Therapeutics, Inc.

Azora Therapeutics is a biopharmaceutical company developing treatments for serious inflammatory diseases. Its lead program, AT177, is an oral, colon-targeted aryl hydrocarbon receptor agonist in development for ulcerative colitis.

Azora Therapeutics, Inc. is headquartered in US.

Azora Therapeutics, Inc. (AZR) stock trades at $3.81 with a market capitalization of $10.00M. The stock is valued at a negative price-to-earnings (P/E) ratio of -0.20, reflecting a net loss over the last twelve months, price-to-book of 3117.50, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $1.31 and $8.25, and currently trades 53.8% below its 52-week high.

On profitability, Azora Therapeutics, Inc. generates a return on equity (ROE) of -160.00% (negative, reflecting a net loss), return on capital employed of -264.70%.

Official website: azoratherapeutics.com

Azora Therapeutics, Inc. (AZR) — frequently asked questions

What is Azora Therapeutics, Inc. (AZR) stock price today?

Azora Therapeutics, Inc. (AZR) is currently trading at $3.81, down 6.85% today.

What is AZR P/E ratio?

Azora Therapeutics, Inc.'s P/E ratio is -0.20. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is AZR return on equity (ROE)?

Azora Therapeutics, Inc.'s return on equity (ROE) is -160.00%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Azora Therapeutics, Inc.'s market cap?

Azora Therapeutics, Inc. has a market capitalization of $10.00M.

Does AZR pay a dividend?

Azora Therapeutics, Inc. is not currently showing a dividend yield in our data, which means no recent cash dividend was recorded for it.

How much debt does AZR carry?

Azora Therapeutics, Inc. has a debt-to-equity ratio of 0.00. That compares total borrowings with shareholders' equity: a figure under 1 means equity exceeds debt.

What is AZR's profit margin?

Azora Therapeutics, Inc. reports a net profit margin of 0.00% — the share of revenue left after every cost, including tax and interest.

What sector is AZR in?

Azora Therapeutics, Inc. is classified under Healthcare, in the Medical - Pharmaceuticals industry. Ratios are most informative compared with other companies in the same industry rather than across the whole market.

Which exchange is AZR listed on?

Azora Therapeutics, Inc. trades on NASDAQ under the ticker AZR.

What is AZR's 52-week range?

Over the last year Azora Therapeutics, Inc. has traded between $1.31 and $8.25.

Related Healthcare Stocks

RPRX Royalty Pharma plc $68.54 -1.12% CORT Corcept Therapeutics Incorporated $69.46 -4.77% LQDA Liquidia Corporation $56.37 -1.81% PBH Prestige Consumer Healthcare Inc. $48.05 +4.03% QUIT Achieve Life Sciences, Inc. $6.11 -3.32% HITI High Tide Inc. $2.38 -3.85% TRXB TRex Bio Inc. $11.83 -13.46% LLY Eli Lilly and Company $1434.26 -0.64% JNJ Johnson & Johnson $282.55 -1.12% ABBV AbbVie Inc. $294.67 -0.12% UNH UnitedHealth Group Incorporated Common Stock (DE) $412.02 +1.12% MRK Merck & Company, Inc. Common Stock (new) $144.46 -2.23%

Popular Stocks

Apple (AAPL)Microsoft (MSFT)NVIDIA (NVDA)Alphabet (GOOGL)Amazon (AMZN)Meta (META)Tesla (TSLA)Broadcom (AVGO)JPMorgan (JPM)Visa (V)

Screens AZR currently matches

On the figures above, Azora Therapeutics, Inc. passes the filters for 4 of our ready-made screens, among them Day Losers Stocks, Penny Stocks, Debt Free Stocks Under $100. Appearing on a screen means the numbers meet its filters today and nothing more; the list is rebuilt whenever the data changes.

Day Losers StocksPenny StocksDebt Free Stocks Under $100Nano Cap Stocks

Related stock screens

High ROE Healthcare StocksLow P/E Healthcare StocksHigh Net Margin Healthcare StocksDividend Healthcare StocksLow Debt Healthcare StocksHigh ROE StocksLow P/E StocksHigh Net Margin StocksDividend StocksLow Debt StocksNasdaq High ROE StocksAll stock screens
Run Stock Screener Investing Guides

Data for information only, not investment advice. Figures may be delayed or inaccurate; verify against company filings. See our disclaimer.